CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: IST1 (ImmuneEditome ID:9798)

1. Gene summary of enriched editing regions for IST1

check button Gene summary
Gene informationGene symbol

IST1

Gene ID

9798

GeneSynonymsCHMP8|OLC1
GeneCytomap

16q22.2

GeneTypeprotein-coding
GeneDescriptionIST1 homolog|IST1, ESCRT-III associated factor|IST1, endosomal sorting complex required for transport-III component|charged multivesicular body protein 8|increased sodium tolerance 1 homolog|overexpressed in lung cancer 1|putative MAPK-activating protein PM28
GeneModificationdate20230404
UniprotIDE9PF00;H3BUI0;J3QQP8;H3BRE2;H3BQF7;H3BPP6;H3BMU1;H3BQ38;F5GXM3;J3KR23
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr16:71910303-71910468:+ENST00000538565.4ENSG00000182149.19IST1ncRNA_intronicAluYm1,MER44Bchr16:71910303-71910468:+.alignment
chr16:71910303-71910468:+ENST00000566536.4ENSG00000182149.19IST1ncRNA_intronicAluYm1,MER44Bchr16:71910303-71910468:+.alignment
chr16:71925539-71927391:+ENST00000538565.4ENSG00000182149.19IST1ncRNA_intronicAluSz,AluSg,AluJr4,AluY,AluSx1,L1ME2chr16:71925539-71927391:+.alignment
chr16:71925539-71927391:+ENST00000541180.1ENSG00000182149.19IST1ncRNA_intronicAluSz,AluSg,AluJr4,AluY,AluSx1,L1ME2chr16:71925539-71927391:+.alignment


Top

2. Tumor-specific enriched editing regions for IST1


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr16:71925539-71927391:+ESCAPathEER1.5071e-021.4961e-020.2782image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000182149.19,IST1COADEAG4.3236e-023.2041e-024.4172e-04image
chr16:71925539-71927391:+OVEER1.2470e-022.0561e-021.7299e-02image
ENSG00000182149.19,IST1OVEAG3.9850e-043.0943e-031.0611e-02image

Top

3. Enriched editing regions and immune related genes for IST1


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for IST1


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

5. Enriched editing regions and immune infiltration for IST1


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr16:71925539-71927391:+BRCAEERB_cells_naive1.3013e-02-0.2037image
ENSG00000182149.19,IST1BRCAEAGB_cells_naive8.8982e-03-0.2001image
chr16:71925539-71927391:+CESCEERMacrophages_M08.1902e-03-0.4124image
ENSG00000182149.19,IST1COADEAGDendritic_cells_activated1.3906e-020.3360image
ENSG00000182149.19,IST1HNSCEAGNK_cells_activated1.2594e-020.5226image
chr16:71925539-71927391:+KIRCEERDendritic_cells_activated4.3963e-020.1693image
chr16:71925539-71927391:+KIRPEERNK_cells_resting2.1977e-020.2386image
ENSG00000182149.19,IST1KIRPEAGNK_cells_resting1.8999e-020.2366image
chr16:71925539-71927391:+LAMLEERMonocytes4.3929e-03-0.5500image
chr16:71925539-71927391:+LGGEERPlasma_cells4.3147e-020.2199image
ENSG00000182149.19,IST1LGGEAGT_cells_follicular_helper4.7403e-020.2073image
chr16:71925539-71927391:+LUADEERDendritic_cells_resting4.7370e-02-0.1638image
ENSG00000182149.19,IST1LUADEAGMast_cells_activated5.4160e-03-0.2238image
chr16:71925539-71927391:+LUSCEERT_cells_CD4_memory_resting1.5810e-04-0.3129image
ENSG00000182149.19,IST1LUSCEAGDendritic_cells_activated8.8955e-040.2695image
ENSG00000182149.19,IST1OVEAGMacrophages_M14.3815e-02-0.2528image
ENSG00000182149.19,IST1PCPGEAGPlasma_cells1.4941e-020.5356image
chr16:71925539-71927391:+PRADEERB_cells_naive4.0748e-020.2768image
ENSG00000182149.19,IST1PRADEAGMonocytes2.5146e-02-0.2866image
chr16:71925539-71927391:+STADEERNeutrophils1.9053e-030.3038image
chr16:71925539-71927391:+THCAEERT_cells_CD4_memory_resting2.5828e-020.2106image
ENSG00000182149.19,IST1UCECEAGT_cells_gamma_delta3.3801e-020.4440image


Top

6. Enriched editing regions and immune gene sets for IST1


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000182149.19,IST1BLCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG7.8287e-030.2632image
chr16:71925539-71927391:+BLCAGSVA_HALLMARK_PANCREAS_BETA_CELLSEER3.9852e-030.2884image
ENSG00000182149.19,IST1BRCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.7689e-040.2755image
chr16:71925539-71927391:+BRCAGSVA_HALLMARK_ADIPOGENESISEER4.4785e-040.2849image
ENSG00000182149.19,IST1CESCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.1425e-030.4743image
chr16:71925539-71927391:+CESCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.2135e-030.4700image
ENSG00000182149.19,IST1COADGSVA_HALLMARK_PROTEIN_SECRETIONEAG4.8726e-02-0.2721image
chr16:71925539-71927391:+GBMGSVA_HALLMARK_GLYCOLYSISEER2.8718e-030.4648image
ENSG00000182149.19,IST1HNSCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG4.1691e-03-0.5859image
ENSG00000182149.19,IST1KIRCGSVA_HALLMARK_UV_RESPONSE_UPEAG1.1437e-040.3160image
chr16:71925539-71927391:+KIRCGSVA_HALLMARK_UV_RESPONSE_UPEER8.5219e-050.3237image
ENSG00000182149.19,IST1KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.0769e-04-0.3812image
chr16:71925539-71927391:+KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEER5.9694e-03-0.2846image
ENSG00000182149.19,IST1LAMLGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.5439e-030.4583image
chr16:71925539-71927391:+LAMLGSVA_HALLMARK_INFLAMMATORY_RESPONSEEER1.7143e-02-0.4722image
chr16:71925539-71927391:+LGGGSVA_HALLMARK_NOTCH_SIGNALINGEER2.8711e-03-0.3196image
ENSG00000182149.19,IST1LGGGSVA_HALLMARK_NOTCH_SIGNALINGEAG3.1290e-03-0.3049image
chr16:71925539-71927391:+LUADGSVA_HALLMARK_MYOGENESISEER2.3664e-050.3410image
ENSG00000182149.19,IST1LUADGSVA_HALLMARK_MYOGENESISEAG2.3388e-050.3348image
chr16:71925539-71927391:+LUSCGSVA_HALLMARK_UV_RESPONSE_UPEER3.8405e-030.2420image
ENSG00000182149.19,IST1LUSCGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG1.6875e-020.1955image
ENSG00000182149.19,IST1PAADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG3.5954e-02-0.2512image
ENSG00000182149.19,IST1PCPGGSVA_HALLMARK_ADIPOGENESISEAG5.7003e-03-0.5945image
ENSG00000182149.19,IST1STADGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.0069e-020.1884image
chr16:71925539-71927391:+STADGSVA_HALLMARK_PROTEIN_SECRETIONEER3.7300e-020.2065image
ENSG00000182149.19,IST1TGCTGSVA_HALLMARK_PROTEIN_SECRETIONEAG6.2003e-030.5530image
chr16:71925539-71927391:+THCAGSVA_HALLMARK_MYC_TARGETS_V1EER4.2897e-050.3765image
ENSG00000182149.19,IST1THCAGSVA_HALLMARK_MYC_TARGETS_V1EAG2.6766e-030.2643image
ENSG00000182149.19,IST1THYMGSVA_HALLMARK_P53_PATHWAYEAG1.4577e-030.6242image
ENSG00000182149.19,IST1UCECGSVA_HALLMARK_HYPOXIAEAG3.2560e-02-0.4468image


Top

7. Enriched editing regions and drugs for IST1


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000182149.19,IST1BLCAAMG.706EAG6.8661e-03-0.2674image
chr16:71925539-71927391:+BLCAMetforminEER4.6433e-02-0.2017image
ENSG00000182149.19,IST1BRCAEmbelinEAG7.7624e-040.2554image
chr16:71925539-71927391:+BRCAABT.263EER5.6061e-040.2803image
ENSG00000182149.19,IST1CESCAZD.2281EAG2.9485e-07-0.6848image
chr16:71925539-71927391:+CESCAZD.2281EER1.4491e-06-0.6792image
chr16:71925539-71927391:+COADMethotrexateEER4.7326e-02-0.2764image
ENSG00000182149.19,IST1GBMMetforminEAG2.1935e-02-0.3528image
chr16:71925539-71927391:+GBMCGP.082996EER2.9264e-03-0.4640image
ENSG00000182149.19,IST1HNSCErlotinibEAG3.5921e-03-0.5935image
ENSG00000182149.19,IST1KIRCCCT007093EAG4.2741e-050.3341image
chr16:71925539-71927391:+KIRCCCT007093EER5.2332e-060.3718image
ENSG00000182149.19,IST1KIRPLapatinibEAG1.3567e-030.3192image
chr16:71925539-71927391:+KIRPLapatinibEER2.8271e-030.3079image
ENSG00000182149.19,IST1LAMLCHIR.99021EAG3.9947e-03-0.4208image
chr16:71925539-71927391:+LAMLCI.1040EER1.2301e-030.6091image
ENSG00000182149.19,IST1LGGAZD.2281EAG4.2077e-02-0.2124image
chr16:71925539-71927391:+LGGGSK269962AEER1.3118e-020.2681image
chr16:71925539-71927391:+LUADABT.888EER3.7172e-040.2897image
ENSG00000182149.19,IST1LUADABT.888EAG1.6941e-030.2517image
chr16:71925539-71927391:+LUSCCCT007093EER4.7313e-030.2366image
ENSG00000182149.19,IST1LUSCCCT007093EAG1.7067e-020.1952image
chr16:71925539-71927391:+OVBIRB.0796EER1.3596e-02-0.3576image
ENSG00000182149.19,IST1OVAUY922EAG1.4176e-020.3053image
ENSG00000182149.19,IST1PAADBMS.536924EAG1.2004e-02-0.3009image
chr16:71925539-71927391:+PAADCHIR.99021EER2.7267e-02-0.2760image
ENSG00000182149.19,IST1PCPGAxitinibEAG6.2673e-030.5892image
ENSG00000182149.19,IST1PRADLapatinibEAG9.3976e-030.3300image
chr16:71925539-71927391:+PRADAZD8055EER1.6370e-02-0.3224image
ENSG00000182149.19,IST1SKCMCyclopamineEAG8.6570e-04-0.5521image
ENSG00000182149.19,IST1STADElesclomolEAG5.8553e-03-0.2226image
chr16:71925539-71927391:+STADGW.441756EER2.0086e-03-0.3024image
ENSG00000182149.19,IST1TGCTJNK.Inhibitor.VIIIEAG4.1451e-03-0.5745image
chr16:71925539-71927391:+THCAAMG.706EER1.0731e-020.2402image
ENSG00000182149.19,IST1THCADocetaxelEAG3.2550e-02-0.1898image
ENSG00000182149.19,IST1THYMAZ628EAG2.3608e-04-0.6945image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType